Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dr Reddy's LaboratoriesFRA:RDDA 83 Earnings per Share (Diluted) is €0.38 as of Jun. 2026. GuruFocus rates FRA:RDDA with a GF Score™ of 83/100 and a GF Value™ of €12.06 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 783 Drug Manufacturers companies, Dr Reddy's Laboratories ranks worse than 68.58% on this metric.
During the past 12 months, Dr Reddy's Laboratories's average EPS without NRIGrowth Rate was -43.20% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was -3.90% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 15.90% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 16.00% per year.
During the past 13 years, Dr Reddy's Laboratories's highest 3-Year average EPS without NRI Growth Rate was 140.00% per year. The lowest was -55.80% per year. And the median was 21.20% per year.
Dr Reddy's Laboratories (FRA:RDDA) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Dr Reddy's Laboratories Earnings per Share (Diluted) Related Terms
Dr Reddy's Laboratories Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Dr Reddy's Laboratories's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr Reddy's Laboratories Earnings per Share (Diluted) Chart
FRA:RDDA vs ZTS: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr Reddy's Laboratories PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's PE Ratio distribution charts can be found below:
* The bar in red indicates where Dr Reddy's Laboratories's PE Ratio falls into.
Dr Reddy's Laboratories Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Dr Reddy's Laboratories's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2026 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of €0.38 mean?
Dr Reddy's Laboratories (FRA:RDDA) has a Earnings per Share (Diluted) of €0.38 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Dr Reddy's Laboratories and its competitors. According to the industry distribution chart, Dr Reddy's Laboratories ranks #537 out of 783 companies in the Drug Manufacturers industry, placing it in the top 68.6%.
Is Dr Reddy's Laboratories' Earnings per Share (Diluted) too high?
Dr Reddy's Laboratories' current Earnings per Share (Diluted) is €0.38. Based on the distribution chart, Dr Reddy's Laboratories ranks #537 out of 783 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Dr Reddy's Laboratories has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dr Reddy's Laboratories' Earnings per Share (Diluted) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Dr Reddy's Laboratories ranks #537 out of 783 companies for Earnings per Share (Diluted). This places Dr Reddy's Laboratories in the lower half of its industry. The industry median Earnings per Share (Diluted) is 9.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.80, based on 783 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Dr Reddy's Laboratories and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr Reddy's Laboratories's current Earnings per Share (Diluted) is €0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr Reddy's Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Dr Reddy's Laboratories (FRA:RDDA) is currently considered Modestly Undervalued. The stock's GF Value™ is €12.06, compared to a current price of €10.10 — trading 16.3% below its estimated fair value. The current Earnings per Share (Diluted) is €0.38. Dr Reddy's Laboratories' overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Dr Reddy's Laboratories (FRA:RDDA), the current Earnings per Share (Diluted) is €0.38 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr Reddy's Laboratories (FRA:RDDA) Overvalued in 2026?
Based on GuruFocus' analysis, Dr Reddy's Laboratories stock appears to be undervalued.
The current stock price of €10.10 is trading 16.3% below its estimated GF Value™ of €12.06.
GuruFocus considers Dr Reddy's Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:RDDA:
Earnings per Share (Diluted): €0.38
GF Value™: €12.06 vs. price of €10.10 (16.3% below fair value)
No single metric tells the full story. See the FRA:RDDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
83GF Score
Get the complete analysis for FRA:RDDA
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RDDA has been successfully added to your 
